RxDoctor Payments Data

Morgan O'Connor, MD

Pain Medicine · Roseville, CANPI 1003227760

Payments from drug & device makers

$2,925in general payments, 2019–2025

Across 59 payments — averaging $49.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Painteq LLC$382
  • Electronic Waveform Lab, Inc.$313
  • Abbott$298
  • AbbVie$288
  • Si-bone, Inc.$229
  • plus $263 from 6 others

What the payments were for

  • Food & beverage$2,925100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)18$1,152
Painteq LLC6$382
Electronic Waveform Lab, Inc.5$313
Abbott9$298
AbbVie2$288
Si-bone, Inc.2$229
Boston Scientific5$85
Scilex Pharmaceuticals Inc.4$59
Arbor Pharmaceuticals, Inc.3$45
Biodelivery Sciences International, Inc.2$32
Zyla Life Sciences, Inc.2$29
Collegium Pharmaceutical, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,925 in reported general payments places this provider in the 55th percentile of 840 pain medicine providers in California.

See all pain medicine providers in California

Medicare billing

Part B allowed, 2024
$132,517
Medicare patients
273
Services billed
1,362

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl31$27,095
Buprenorphine66$18,468
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen352$11,383
OxycontinOxycodone Hcl23$11,119
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen83$2,464
Fentanyl21$2,017
Gabapentin42$1,376
Naloxone Hcl21$1,300
Celecoxib23$1,102
Morphine Sulfate ErMorphine Sulfate53$942
Methocarbamol20$784
Pregabalin66$784
Buprenorphine Hcl24$561
Baclofen38$487
Cyclobenzaprine Hcl40$390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$13$27,09531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 840 pain medicine providers in California.

Other pain medicine in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →